Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Decitabine Based Conditioning and Maintenance in TP53 Mutant AML/MDS
NCT05528354Phase 2Completed
- Sponsor
- Zhejiang University
- Start
- Jun 2022
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax and decitabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Zhejiang University. Primary endpoint: Relapse-free survival at 1 year. Started Jun 2022; status: completed.
02
Drugs
venetoclaxdecitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05528354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05528354.